OPTIMIZER Smart for Heart Failure
(PAS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to study the OPTIMIZER Smart device, which helps manage heart failure symptoms in patients with a specific heart condition. The research targets individuals with moderate heart failure symptoms and a left ventricular ejection fraction between 25-45%. Those who experience symptoms like breathlessness or fatigue due to heart failure, despite medication, might be suitable candidates. The trial will monitor the device's effectiveness and safety for those receiving it as part of their regular care. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of a new treatment.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, it mentions that patients should have been treated with guideline-directed medical therapy, which suggests you may need to continue your current treatment.
What prior data suggests that the OPTIMIZER Smart implant is safe for patients with NYHA functional class III symptoms?
Research has shown that the OPTIMIZER Smart System is generally safe, as previous studies have indicated. Most patients have tolerated the device well. Some studies found it safe and effective for individuals with heart failure. The FDA has already approved the OPTIMIZER Smart for heart failure, confirming it has passed strict safety tests.
Several clinical studies have tested the device and found no major safety issues. Additionally, the OPTIMIZER Smart is compatible with MRI (magnetic resonance imaging) scans, allowing patients to undergo certain imaging tests without concern. While all medical treatments carry some risks, most patients have tolerated the OPTIMIZER Smart well.12345Why are researchers enthusiastic about this study treatment?
The OPTIMIZER Smart is unique because it uses Cardiac Contractility Modulation (CCM) therapy, which is a new approach for treating heart failure. Unlike standard treatments that typically focus on managing symptoms or improving heart pumping efficiency through drugs or devices like pacemakers, CCM therapy directly enhances the heart's natural contraction by sending electrical signals to the heart muscle during its natural beating cycle. Researchers are excited about this treatment because it has the potential to improve heart function and quality of life in patients who are not adequately managed by current options.
What evidence suggests that the OPTIMIZER Smart is effective for NYHA functional class III symptoms?
Research shows that the OPTIMIZER Smart device can improve heart function in people with certain heart conditions. Studies have found that patients can walk farther in six minutes, experience better daily living, and see overall health improvements. After receiving the OPTIMIZER implant, many patients notice steady improvements for up to 24 months. The device enhances the heart's pumping efficiency, leading to better daily activities and symptom relief. This treatment is approved for specific heart conditions and is supported by strong clinical evidence.12367
Who Is on the Research Team?
Rami Kahwash, MD
Principal Investigator
Ohio State University
Raul Weiss, MD
Principal Investigator
Mt. Sinai Miami
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the OPTIMIZER Smart implant and CCM therapy as standard of care
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for all-cause mortality and device-related complications
What Are the Treatments Tested in This Trial?
Interventions
- OPTIMIZER Smart
Find a Clinic Near You
Who Is Running the Clinical Trial?
Impulse Dynamics
Lead Sponsor
Citations
Long‐term clinical experience with cardiac contractility ...
Data show consistent improvements in all effectiveness measures for all groups over the 24 months of follow‐up after Optimizer implant. Similarly, functional ...
2.
impulse-dynamics.com
impulse-dynamics.com/wp-content/uploads/2021/04/2019-Campbell-OSU-Optimizer-Smart-Device-Evaluation-with-Disclaimer.pdf2019-Campbell-OSU-Optimizer-Smart-Device- ...
The OPTIMIZER Smart System, which delivers CCM™ therapy, is indicated to improve 6-minute hall walk distance, quality of life and functional status of NYHA ...
Post Approval Study (PAS) of the OPTIMIZER Smart and ...
Six minute hall walk and functional class also showed improvements in the PMA data. The post-approval study (PAS) protocol has been designed to evaluate long ...
summary of safety and effectiveness data (ssed)
The applicant will conduct a post-approval study (PAS) to provide long term safety and effectiveness data for the OPTIMIZER Smart System.
Safety, Performance, and Efficacy of Cardiac Contractility ...
The present results demonstrate that compared with the prior 3-lead system, the 2-lead Optimizer Smart device delivers equivalent amounts of CCM ...
6.
impulsedynamics.it
impulsedynamics.it/wp-content/uploads/2020/05/13-250-003-01-US-Rev-01-OPT-Smart-System-Patient-Manual.pdfOPTIMIZER® Smart System - Impulse Dynamics
Improving the inherent safety of the OPTIMIZER Smart will allow physicians to expand its use thereby helping more patients with chronic heart failure. This ...
opt smart leads information
The OPTIMIZER Smart IPG is Magnetic Resonance (MR) Conditional, and patients with this device may be scanned safely with magnetic resonance imaging (MRI).
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.